Zanidatamab Plus Chemotherapy Prolongs PFS Over Trastuzumab Plus Chemotherapy in Patients with HER2-positive Advanced Gastro-Oesophageal Adenocarcinoma By Ogkologos - June 1, 2026 114 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HERIZON-GEA-01 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR GreaterGood Is Donating Thousands of Masks to Help Animal Shelters Stay... September 17, 2020 Expressive Writing, What is It? May 12, 2021 Cancer in My Community: How People With Cancer Access Care in... August 12, 2021 Immunotherapy is Beneficial in Gastric and Oesophageal Cancers, Studies Show [ESMO2020... September 21, 2020 Load more HOT NEWS Pediatric MATCH Study Finds More Targetable Genetic Changes than Expected Disease in a dish: Mini-gut organoids and the challenges of bowel... NHS England change of chief executive – what does it mean... ESMO Asia Congress 2024, Singapore, 6-8 December
